Closing comments on A.P. Pharma:
During my last post I covered a majority of the information I wanted to cover on A.P. Pharma’s anti-emetic drug, APF-530. Now I would like to conclude my analysis and present my thesis for investing in APPA.
Here are the key reasons for investing in APPA:
1.) The active compound in APF-530 (granesitron) has a [...]

The oncology market is the third largest pharmaceutical market, behind the cardiovascular and central nervous system (CNS) therapy markets, and is currently experiencing strong growth. Analysts predict that the sector will grow to $60 billion by 2010. The frequency and debilitating nature of chemotherapeutic side-effects are a huge problem that requires the discovery and development [...]